Pharmaceutical - Novo Nordisk, Neurological

Filter

Current filters:

Novo NordiskNeurological

Popular Filters

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

04-11-2014

A new study has suggested that drugs currently being used to treat diabetes also have the potential to…

liraglutidelixisenatideNeurologicalNovo NordiskPharmaceuticalResearchSanofiUK

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

FDA accepts Merck & Co's suvorexant; panel backs Novo's Tresiba and Ryzodeg

09-11-2012

US drug giant Merck & Co (NYSE: MRK) says that the New Drug Application for suvorexant, the company's…

DegludecDiabetesMerck & CoNeurologicalNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegsuvorexantTresiba

Europe's CHMP issues positive opinions on aclidinium, Fycompa, Inlyta and NovoThirteen

27-05-2012

At its regular monthly meeting last week, the European Medicines Agency's Committee for Medicinal Products…

AlmirallBretaris GenuairEisaiEklira GenuairEuropeFycompaInlytaNeurologicalNovo NordiskNovoThirteenOncologyPfizerPharmaceuticalRespiratory and Pulmonary

Back to top